Three distinct vaccine candidates are racing toward human trials in the Democratic Republic of the Congo and Uganda, backed by US$62 million in new funding to confront an outbreak of Bundibugyo Ebola virus — a strain that existing vaccines cannot adequately protect against.
The urgency is real but tempered by recent progress. As of June 2, DRC health authorities confirmed 344 cases with 60 deaths, while Uganda reported 15 confirmed cases and one death — a significant decrease from the more than 1,000 suspected cases reported earlier in the outbreak. That downward trajectory, paired with accelerated vaccine development, offers a rare moment of convergence between outbreak control and scientific innovation.
The challenge lies in a fundamental biological truth: different Ebola viruses wear different surface proteins, making existing vaccines ineffective against this particular strain. The world already has two approved Ebola vaccines — Ervebo and Zabdeno/Mvabea — but both target the Zaire Ebola virus specifically. When the Bundibugyo virus began spreading across the DRC and Uganda, health systems had proven tools that simply didn't work. That gap is what the Coalition for Epidemic Preparedness Innovations aims to close with its funding injection, fast-tracking the development of the first approved vaccine specifically engineered for Bundibugyo protection.
The three candidates taking shape each reflect different technological approaches. The International AIDS Vaccine Initiative, working with the University of Texas Medical Branch, is developing a single-dose vaccine using technology similar to the approved Ervebo. A WHO expert panel called it "the most promising candidate vaccine," though it has only been tested in macaque monkeys so far and is likely seven to nine months away from human trials. Moderna, the biotechnology company behind a COVID mRNA vaccine, is applying its genetic vaccine platform to target Bundibugyo's surface glycoprotein. The third candidate emerges from the University of Oxford and the Serum Institute of India, built on the same viral vector technology used in the Oxford/AstraZeneca COVID vaccine, with human trials potentially beginning within two to three months — the fastest timeline of the three.
Each pathway carries different implications for deployment. The Oxford-Serum vaccine could potentially use a single dose for contacts of confirmed Ebola cases, while health-care workers and front-line responders might require two doses. All three candidates must clear a demanding sequence: proof of safety and effectiveness, regulatory approval, manufacturing at scale, and logistical delivery into vulnerable populations across two countries already stretched by outbreak response.
What makes this moment distinctive is not that vaccines are being developed — the scientific infrastructure exists — but that the funding, political will, and endemic outbreak context have aligned to accelerate timelines. In diseases like Ebola, where outbreaks are relatively rare in the developed world, this convergence is uncommon. The next months will determine whether these three candidates can move from laboratory promise to field reality before the Bundibugyo outbreak gains further ground.